No significant improvement in hepatic steatosis, fibrosis, or biochemical markers (ALT, AST, cholesterol, etc.). Stabilization of CD8+ T lymphocytes and  ZO-1 expression in probiotics group (vs. reduction in placebo). Here, TJP1 is linked to fatty liver disease.